News

The company said that Zomig is the first nasal-delivered prescription medicine approved to treat acute migraine attacks in pediatric patients. The approval came after the FDA’s review of

Rapivab is an intravenous (IV) treatment indicated in the US for acute uncomplicated influenza in adults aged 18 years and older. bioCSL general manager and senior vice-president Dr

As part of the deal, the two firms will carry out collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo’s choice, with a

As part of the deal, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. The company

The collaboration is aimed to advance understanding of the biological mechanisms that underpin these conditions and develop new treatments based on this knowledge. As part of the deal,

The company was also notified by FDA’s regulatory advisors to proceed with the clinical trial of its investigational universal flu vaccine. The IND application will allow the company

The transaction, valued at $75 per Kythera share, is subject to the fulfillment of certain customary conditions. According to the company, the fixed-value transaction consideration will be payable

"The orphan drug designation for XOMA 358 recognizes its potential to address a significant unmet medical need for patients with congenital hyperinsulinism. Patients with hyperinsulinism, a rare and

This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has four US patents and two Canadian patents issued in this area with